Evidence map›Paper›PMID 27034783›Full record

ArticleJournal of gastrointestinal oncology2016

Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma.

Ellie Chan, Lizette Vila Duckworth, Ahmad Alkhasawneh, Tania Zuluaga Toro, Xiaomin Lu, Kfir Ben-David, Steven J Hughes, Georgios Rossidis, Robert Zlotecki, Judith Lightsey and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. The oncologist · 2019
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Ellie Chan1 Division of Hematology & Oncology, Department of Medicine, University of California San Francisco, Fresno Medical Education Program, California, USA ; 2 Department of Pathology, Immunology and Laboratory Medicine, 3 Department of Biostatistics, 4 Department of Surgery, 5 Department of Radiation Oncology, 6 Division of Hematology & Oncology, Department of Medicine, University of Florida, College of Medicine, Gainesville, FL, USA.
Lizette Vila Duckworth1 Division of Hematology & Oncology, Department of Medicine, University of California San Francisco, Fresno Medical Education Program, California, USA ; 2 Department of Pathology, Immunology and Laboratory Medicine, 3 Department of Biostatistics, 4 Department of Surgery, 5 Department of Radiation Oncology, 6 Division of Hematology & Oncology, Department of Medicine, University of Florida, College of Medicine, Gainesville, FL, USA.
Ahmad Alkhasawneh1 Division of Hematology & Oncology, Department of Medicine, University of California San Francisco, Fresno Medical Education Program, California, USA ; 2 Department of Pathology, Immunology and Laboratory Medicine, 3 Department of Biostatistics, 4 Department of Surgery, 5 Department of Radiation Oncology, 6 Division of Hematology & Oncology, Department of Medicine, University of Florida, College of Medicine, Gainesville, FL, USA.
Tania Zuluaga Toro1 Division of Hematology & Oncology, Department of Medicine, University of California San Francisco, Fresno Medical Education Program, California, USA ; 2 Department of Pathology, Immunology and Laboratory Medicine, 3 Department of Biostatistics, 4 Department of Surgery, 5 Department of Radiation Oncology, 6 Division of Hematology & Oncology, Department of Medicine, University of Florida, College of Medicine, Gainesville, FL, USA.
Xiaomin Lu1 Division of Hematology & Oncology, Department of Medicine, University of California San Francisco, Fresno Medical Education Program, California, USA ; 2 Department of Pathology, Immunology and Laboratory Medicine, 3 Department of Biostatistics, 4 Department of Surgery, 5 Department of Radiation Oncology, 6 Division of Hematology & Oncology, Department of Medicine, University of Florida, College of Medicine, Gainesville, FL, USA.
Kfir Ben-David1 Division of Hematology & Oncology, Department of Medicine, University of California San Francisco, Fresno Medical Education Program, California, USA ; 2 Department of Pathology, Immunology and Laboratory Medicine, 3 Department of Biostatistics, 4 Department of Surgery, 5 Department of Radiation Oncology, 6 Division of Hematology & Oncology, Department of Medicine, University of Florida, College of Medicine, Gainesville, FL, USA.
Steven J Hughes1 Division of Hematology & Oncology, Department of Medicine, University of California San Francisco, Fresno Medical Education Program, California, USA ; 2 Department of Pathology, Immunology and Laboratory Medicine, 3 Department of Biostatistics, 4 Department of Surgery, 5 Department of Radiation Oncology, 6 Division of Hematology & Oncology, Department of Medicine, University of Florida, College of Medicine, Gainesville, FL, USA.
Georgios Rossidis1 Division of Hematology & Oncology, Department of Medicine, University of California San Francisco, Fresno Medical Education Program, California, USA ; 2 Department of Pathology, Immunology and Laboratory Medicine, 3 Department of Biostatistics, 4 Department of Surgery, 5 Department of Radiation Oncology, 6 Division of Hematology & Oncology, Department of Medicine, University of Florida, College of Medicine, Gainesville, FL, USA.
Robert Zlotecki1 Division of Hematology & Oncology, Department of Medicine, University of California San Francisco, Fresno Medical Education Program, California, USA ; 2 Department of Pathology, Immunology and Laboratory Medicine, 3 Department of Biostatistics, 4 Department of Surgery, 5 Department of Radiation Oncology, 6 Division of Hematology & Oncology, Department of Medicine, University of Florida, College of Medicine, Gainesville, FL, USA.
Judith Lightsey1 Division of Hematology & Oncology, Department of Medicine, University of California San Francisco, Fresno Medical Education Program, California, USA ; 2 Department of Pathology, Immunology and Laboratory Medicine, 3 Department of Biostatistics, 4 Department of Surgery, 5 Department of Radiation Oncology, 6 Division of Hematology & Oncology, Department of Medicine, University of Florida, College of Medicine, Gainesville, FL, USA.
Karen C Daily1 Division of Hematology & Oncology, Department of Medicine, University of California San Francisco, Fresno Medical Education Program, California, USA ; 2 Department of Pathology, Immunology and Laboratory Medicine, 3 Department of Biostatistics, 4 Department of Surgery, 5 Department of Radiation Oncology, 6 Division of Hematology & Oncology, Department of Medicine, University of Florida, College of Medicine, Gainesville, FL, USA.
Long Dang1 Division of Hematology & Oncology, Department of Medicine, University of California San Francisco, Fresno Medical Education Program, California, USA ; 2 Department of Pathology, Immunology and Laboratory Medicine, 3 Department of Biostatistics, 4 Department of Surgery, 5 Department of Radiation Oncology, 6 Division of Hematology & Oncology, Department of Medicine, University of Florida, College of Medicine, Gainesville, FL, USA.
Carmen J Allegra1 Division of Hematology & Oncology, Department of Medicine, University of California San Francisco, Fresno Medical Education Program, California, USA ; 2 Department of Pathology, Immunology and Laboratory Medicine, 3 Department of Biostatistics, 4 Department of Surgery, 5 Department of Radiation Oncology, 6 Division of Hematology & Oncology, Department of Medicine, University of Florida, College of Medicine, Gainesville, FL, USA.
Brent King1 Division of Hematology & Oncology, Department of Medicine, University of California San Francisco, Fresno Medical Education Program, California, USA ; 2 Department of Pathology, Immunology and Laboratory Medicine, 3 Department of Biostatistics, 4 Department of Surgery, 5 Department of Radiation Oncology, 6 Division of Hematology & Oncology, Department of Medicine, University of Florida, College of Medicine, Gainesville, FL, USA.
Thomas J George1 Division of Hematology & Oncology, Department of Medicine, University of California San Francisco, Fresno Medical Education Program, California, USA ; 2 Department of Pathology, Immunology and Laboratory Medicine, 3 Department of Biostatistics, 4 Department of Surgery, 5 Department of Radiation Oncology, 6 Division of Hematology & Oncology, Department of Medicine, University of Florida, College of Medicine, Gainesville, FL, USA.
Florida College · US

Funding

Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
UF Clinical and Translational Science AwardUL1TR000064 · NCATS · UNIVERSITY OF FLORIDA · PI NELSON, DAVID R · 2012 to 2014
$12.2M
NCATS NIH HHS UL1 TR000064NCATS NIH HHS UL1 TR001427
6 · The paper itself

Abstract

backgroundTargeting human epidermal growth factor receptor 2 (HER2) with trastuzumab in metastatic esophagogastric adenocarcinoma (EGA) improves survival. The impact of HER2 inhibition in combination with chemoradiotherapy (CRT) in early stage EGA is under investigation. This study analyzed the pattern of HER2 overexpression in matched-pair tumor samples of patients who underwent neoadjuvant CRT followed by surgery.

methodsAll patients with EGA who underwent standard neoadjuvant CRT followed by esophagectomy at the University of Florida were included. Demographics, risk factors, tumor features, and outcome data were analyzed. Descriptive statistics, Chi-square exact test, uni- and multivariate analyses, and Kaplan Meier method were used. HER2 expression determined by immunohistochemical (IHC) was scored as negative (0, 1+), indeterminate (2+) or positive (3+).

resultsAmong 49 sequential patients (41 M/8 F) with matched-pair tumor samples, 9/49 patients (18%) had pathologic complete response (pCR), 10/49 had near pCR or not enough tumor (NET) to examine in the post- treatment samples. Patients with initial HER2 negativity demonstrated conversion to HER2 positivity after neoadjuvant CRT (7/30 cases; 23%). Baseline HER2 overexpression was more common in lower stage/node negative patients (67% in stages I, IIA vs. 33% in stages IIB, III) and did not correlate with treatment response or survival.

conclusionsAlthough limited by a relatively small sample size, our study failed to demonstrate that baseline HER2 protein over-expression in EGA predicts response to standard CRT. However, our data suggested that HER2 was up regulated by CRT resulting in unreliable concordance between pre-treatment (pre-tx) and post-treatment (post-tx) samples. Pre-therapy HER2 expression may not reliably reflect the HER2 status of persistent or recurrent disease.

Indexed as

Chemoradiationesophagogastric adenocarcinoma (EGA)human epidermal growth factor receptor 2 (HER2)

Identifiers

PMID27034783
PMCPMC4783750
OpenAlexW2209957364

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.